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Acquis et limites 
dans les thérapies ciblées anti-HER 2
T. Petit*1
Pour en savoir plus sur les thérapies ciblées1
Quelques dates repères et références princeps
• 1978 : EGFR, ErbB1 HER1 : découverte du premier récepteur de tyrosine 
kinase par Stanley Cohen à l’université de Vanderbilt, USA.
• 1982-1984 : l’oncogène neu est découvert par un groupe de chercheurs du 
Massachusett Institute of Technology (MIT) dont R.A. Weinberg. Il est aussi 
dénommé HER 2, ErbB2 ou p 185.
• 1984-1986 : Erb 2 ou HER2 (pour human epidermal growth factor 2) est 
cloné par un groupe de chercheurs, dont Ullrich et Coussens au Japon. Le gène 
neu et HER2 est habituellement appelé HER2/neu en référence au travail de 
R Weinberg et A Ullrich.
• 1985-1986 : l’oncogène neu est cloné, séquencé et localisé sur le chromo-
some 17.
• 1987 : Slamon et al. montrent que ces oncogènes peuvent être surexprimés 
dans les cancers du sein (Science) et qu’ils sont reliés à un mauvais pronostic.
Le gène HER2/neu ou encore c-erb B2 code pour un récepteur transmem-
branaire possédant une activité tyrosine kinase, la p185 proche dans sa struc-
ture du récepteur de l’EGF ; il est situé sur le chromosome 17. Il participe à la 
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signalisation de la croissance cellulaire, il induit AKT/PKB et inhibe les voies 
inductrices de l’apoptose.
Une surexpression de la p185 HER2/neu est retrouvée dans 20 % environ 
des cancers du sein et est associée à un taux de rechute et à une mortalité accrus.
Le trastuzumab
D’abord testé dans des essais de phase II, le trastuzumab, anticorps monoclonal 
humanisé anti-c erbB2, ayant entraîné des régressions tumorales objectives chez 
des patientes métastatiques d’un cancer du sein, surexprimant HER2, a été utilisé 
avec un bénéfi ce franc dans un essai de phase III, comparant une chimiothérapie 
de première ligne à la même chimiothérapie associée à celui-ci (Slamon, 1998, 
ASCO). La diff érence entre les deux bras s’avérait majeure et historique (MacNeil, 
JNCI, 1998).
En revanche, très rapidement, est apparue une toxicité cardiaque inhabituelle 
avec l’adriamycine, et non retrouvée avec les taxanes.
Ces résultats spectaculaires ont fait poser très vite la question du dosage en 
routine de HER2 (Radvin, 1999) et de l’utilisation du trastuzumab en situation 
adjuvante ou néadjuvante (Clark, JNCI, 1998 ; Piccart, EJC, 2000 ; Dowsett, 
2000).
En 2002, Frédérique Penault-Llorca publiait avec le GEFPICS des proto-
coles de dosage et d’interprétation (Ann Pathol, 2002). En 2003, une synthèse 
reprenant les données publiées défi nissait la place de l’association trastuzumab-
taxanes dans le Bulletin du Cancer (Campone, Merlin, Fumoleau). De nombreux 
essais sont alors activés pour répondre aux nombreuses questions posées : schéma 
 d’administration, quelles associations, combien de temps, etc.
En 2005, les recommandations de Saint-Paul-de-Vence (Oncologie, 7 : 
342-79) défi nissaient la stratégie optimale de détermination du statut HER2 
et des choix thérapeutiques en cas de tumeurs HER2 +. Suite aux résultats des 
grandes études princeps (Piccart, Romond, NEJM, 2005), l’INCa a émis un 
protocole temporaire d’utilisation du trastuzumab en situation adjuvante.
En 2011, la veille bibliographique de Saint-Paul-de-Vence a actualisé les 
recommandations en situation adjuvante pour les tumeurs HER2+, quant aux 
associations et à la durée du traitement (Oncologie, 13 : 698-702).
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L’une des questions posées dans les recommandations de l’INCa qui viennent 
d’être mises en ligne est consacrée à la question de l’indication d’un traitement 
par trastuzumab associé à une chimiothérapie, en cas de tumeur infraclinique 
(question 9). Bien des questions restent encore en suspens, sans même évoquer 
les associations en situation métastatique avec d’autres thérapies ciblées.
Quelques exemples de controverses
• Durée optimale du traitement ? Pas de données actuellement disponibles 
(essais terminés en attente de résultats).
• Faut-il toujours utiliser des anthracyclines chez les patientes HER2+ ?
• Les nouvelles thérapies telles que le lapatinib, le trastuzumab DM1, et le 
pertuzumab qui ont fait la preuve de leur association avec le trastuzumab en 
métastatique doivent-elles être utilisées en adjuvant ? (essais en cours) Et si c’est 
le cas, en association ou à la place ou de façon séquentielle ?
• Peut-on envisager de prescrire le trastuzumab sans chimiothérapie ? Que 
sait-on des associations avec l’hormonothérapie ?
Références
Slamon DJ, Clark GM, Wong SG (1987) Human breast cancer: correlation of 
relapse and survival with amplifi cation of the HER-2/neu oncogène. Science 
235: 177-82
Th e HER-2/neu oncogene is a member of the erbB-like oncogene family, and 
is related to, but distinct from, the epidermal growth factor receptor. Th is 
gene has been shown to be amplifi ed in human breast cancer cell lines. In the 
current study, alterations of the gene in 189 primary human breast cancers were 
investigated. HER-2/neu was found to be amplifi ed from 2- to greater than 
20-fold in 30% of the tumors. Correlation of gene amplifi cation with several 
disease parameters was evaluated. Amplifi cation of the HER-2/neu gene was 
a signifi cant predictor of both overall survival and time to relapse in patients 
with breast cancer. It retained its signifi cance even when adjustments were made 
for other known prognostic factors. Moreover, HER-2/neu amplifi cation had 
greater prognostic value than most currently used prognostic factors, including 
hormonal-receptor status, in lymph node-positive disease. Th ese data indicate 
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that this gene may play a role in the biologic behavior and/or pathogenesis of 
human breast cancer.
Beuzeboc P, Scholl S, Garau XS (1999) Herceptin, a monoclonal humanized 
antibody anti-HER2: a major therapeutic progress in breast cancers overex-
pressing this oncogene? Bull Cancer 86: 544-9
HER2 is overexpressed in about 25% to 30% of breast cancers and associated 
with poor prognosis, resistance to hormonotherapy and lack of sensitivity to 
CMF-based adjuvant chemotherapy. Herceptin (trastuzumab), a humanized 
monoclonal antibody, administered as a single agent, produces objective responses 
in phase II trials in patients with metastatic breast cancers overexpressing HER2. 
It has shown a substantial benefi t in a phase III trial which compares a standard 
fi rst line chemotherapy (doxorubicin and cyclophosphamide or taxol alone) 
to the same chemotherapy with Herceptin in metastatic breast cancer. Th e 
Herceptin arm had signifi cantly higher response rate (+ 53%), an improvement 
in the median duration of response (+ 57%) as well as in time to progression 
(+ 65%) compared to chemotherapy alone.
Ravdin PM (1999) Should HER2 status be routinely measured for all breast 
cancer patients? Semin Oncol (4 Suppl 12): 117-23
Several recent publications have re-opened the question of whether HER2 status 
should be determined for all patients with newly diagnosed breast cancer. Th e 
barrier in the past to the use of HER2 has been the nonstandardization of HER2 
status determination, which is the major caveat to its use today. Two test kits have 
been recently approved by the Food and Drug Administration for HER2 testing, 
one for determining HER2 amplifi cation by fl uorescence in situ hybridization and 
the other for measuring HER2 overexpression by immunohistochemistry. Neither 
of these tests, nor any of the other myriad tests used for HER2 determinations, has 
been validated in all the potential arenas for the use of HER2: refi nement of estimates 
of prognosis of untreated low-risk patients, selection among treatment options 
for adjuvant therapy, and selection of patients for treatment with trastuzumab 
(Herceptin; Genentech, San Francisco, CA). Th e nonstandardization of testing 
has led to confl icting results and controversy as to the value of HER2 in evaluating 
breast cancer patient prognosis and the selection among therapeutic options. Th us, 
testing for HER2 is not yet routine for patients with newly diagnosed breast cancer, 
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although it is of value for patients who develop metastatic disease and who need 
to know if they are candidates for trastuzumab.
Piccart MJ, Di Leo A, Hamilton A (2000) HER2. a ‘predictive factor’ ready 
to use in the daily management of breast cancer patients? Eur J Cancer 14: 
1755-61
Th e past few years have witnessed an exponential increase in studies trying to 
identify molecular markers in patients with breast tumours that might predict for 
the success or failure of hormonal therapy or chemotherapy. HER2, a tyrosine 
kinase membrane receptor of the epidermal growth factor receptor family, has 
been the most widely studied marker in this respect. Th is paper attempts to 
critically review to what extent HER2 may improve ‘treatment individualisation’ 
for the breast cancer patient.
Nabholtz JM, Slamon D (2001) New adjuvant strategies for breast cancer: 
meeting the challenge of integrating chemotherapy and trastuzumab 
(Herceptin). Semin Oncol 1 (Suppl 3): 1-12
Improvements in breast cancer treatment will arrive with better understanding of 
its biology and through biologically oriented therapeutic interventions as well as 
better identifi cation of patient populations susceptible to benefi t from classical 
therapies (endocrine and chemotherapy). Among the new chemotherapies, the 
taxanes have emerged as powerful agents in the treatment of metastatic breast 
cancer and a strong emphasis has been pursued into their development in the 
adjuvant setting. Two generations of adjuvant pivotal trials with taxanes have 
been developed. Th e fi rst generation compared taxane/anthracycline regimens to 
nontaxane combinations or sequence regimens. Th e second generation of trials is 
presently being performed and contains taxanes in both arms, comparing their 
use in combination or in sequence. Trastuzumab (Herceptin; Genentech, Inc, 
South San Francisco, CA) is the fi rst biologic modifi er with signifi cant activity in 
advanced breast cancer patients amplifying the HER2 gene. As a consequence of 
these results, including improved survival in the metastatic setting, this agent has 
been very quickly considered for adjuvant development. However, the signifi cant 
cardiac toxicity observed with trastuzumab/anthracycline combinations has led 
to two main strategies for integrating trastuzumab in the adjuvant setting: (1) 
addition of trastuzumab to mostly anthracycline-based programs (sequential 
approach); and (2) biology-oriented strategy based on synergism between 
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trastuzumab and chemotherapy agents. Large-scale clinical research programs 
are presently being developed and will create a challenge for clinical researchers. 
Th e adequate scientifi c hypothesis, related to the pivotal studies of trastuzumab 
in the adjuvant setting, require large sample sizes (several thousand patients) and 
a very strict selection of the patient population (tumors amplifying the HER2 
gene). Success in a timely fashion requires global collaboration, dedication to high-
standard clinical research, and awareness of all available protocols by oncologists 
and patients with breast cancer.
Leyland-Jones B (2002) Trastuzumab: hopes and realities. Lancet Oncol 3: 
137-44
Despite improvements in care of patients with breast cancer, up to half develop 
refractory or resistant disease. Th ere is therefore a need for new, modifi ed anticancer 
therapies with greater eff ectiveness, tolerability to patients, and tumour specifi city. 
Trastuzumab (Herceptin) is the fi rst clinically available oncogene-targeted 
therapeutic agent for treatment of solid tumours. Clinical trials in patients positive 
for HER2 (human epidermal-growth-factor receptor 2) show that trastuzumab is 
eff ective and well tolerated; as a single-agent second-line or third-line treatment, the 
drug produced durable tumour responses. First-line trastuzumab in combination 
with chemotherapy, particularly paclitaxel, signifi cantly improved time to disease 
progression, duration of response, and time to treatment failure. Combination 
therapy resulted in a 25% improvement in overall survival compared with 
chemotherapy alone. Patients with HER2 gene amplifi cation, high overexpression 
of HER2 (3+ on immunohisto-chemistry), or both features, obtained the greatest 
clinical benefi t. Trastuzumab is the fi rst monoclonal antibody with effi  cacy in 
breast cancer and the fi rst gene-product-targeted therapy to produce a signifi cant 
survival advantage in this disease. Trastuzumab is likely to fi nd its ultimate role 
in the adjuvant setting. Its development provides a model for the integration of 
other gene-targeted therapies into breast-cancer management to improve survival 
and quality of life.
Baselga J, Perez EA, Pienkowski T, Bell R (2006) Adjuvant trastuzumab: a 
milestone in the treatment of HER-2-positive early breast cancer. Oncologist 
11 (Suppl 1): 4-12
Penault-Llorca F, Balaton A, Sabourin JC, Le Doussal V; Groupe d’évaluation 
des facteurs pronostiques par immunohistochimie dans les cancers du 
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sein (GEFPICS) (2002) Immunochemistry evaluation of HER2 status in 
infi ltration breast cancer: technical protocol and interpretation guidelines. 
Ann Pathol 2: 150-7
Campone M, Merlin JL, Fumoleau P (2003) Role of the combination of 
trastuzumab and taxanes in the therapeutic management of cancer of the 
breast: from preclinical data to clinical application. Bull Cancer 90: 614-22
Taxanes are major drugs in the treatment of breast metastatic cancer. Since 1990, the 
mechanisms implicated in carcinogenesis are better understood and the oncoprotein 
HER2 is a potential target. Trastuzumab is a monoclonal antibody that binds to 
this transmembrane glycoprotein. Th is antibody demonstrated a signifi cant activity 
in clinical trials. In this review, we discuss the preclinical (mechanisms of action) 
and clinical data with the combination of trastuzumab and taxanes.
Romond EH, Perez EA, Bryant J (2005) Trastuzumab plus adjuvant chemotherapy 
for operable HER2-positive breast cancer. N Engl J Med 353: 1673-84
We present the combined results of two trials that compared adjuvant chemotherapy 
with or without concurrent trastuzumab in women with surgically removed 
HER2-positive breast cancer.
Th e National Surgical Adjuvant Breast and Bowel Project trial B-31 compared 
doxorubicin and cyclophosphamide followed by paclitaxel every 3 weeks (group 1) 
with the same regimen plus 52 weeks of trastuzumab beginning with the fi rst dose 
of paclitaxel (group 2). Th e North Central Cancer Treatment Group trial N9831 
compared three regimens: doxorubicin and cyclophosphamide followed by weekly 
paclitaxel (group A), the same regimen followed by 52 weeks of trastuzumab after 
paclitaxel (group B), and the same regimen plus 52 weeks of trastuzumab initiated 
concomitantly with paclitaxel (group C). Th e studies were amended to include a 
joint analysis comparing groups 1 and A (the control group) with groups 2 and 
C (the trastuzumab group). Group B was excluded because trastuzumab was not 
given concurrently with paclitaxel.
By March 15, 2005, 394 events (recurrent, second primary cancer, or death 
before recurrence) had been reported, triggering the fi rst scheduled interim 
analysis. Of these, 133 were in the trastuzumab group and 261 in the control 
group (hazard ratio, 0.48; P < 0.0001). Th is result crossed the early stopping 
boundary. Th e absolute diff erence in disease-free survival between the trastuzumab 
group and the control group was 12 percent at three years. Trastuzumab therapy 
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was associated with a 33 percent reduction in the risk of death (P = 0.015). Th e 
three-year cumulative incidence of class III or IV congestive heart failure or death 
from cardiac causes in the trastuzumab group was 4.1 percent in trial B-31 and 
2.9 percent in trial N9831.
Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide 
improves outcomes among women with surgically removed HER2-positive breast 
cancer. (ClinicalTrials.gov numbers, NCT00004067 and NCT00005970.)
Viani GA, Afonso SL, Stefano EJ (2007) Adjuvant trastuzumab in the 
treatment of her-2-positive early breast cancer: a meta-analysis of published 
randomized trials. BMC Cancer 7: 153
Breast cancer is the most common cancer in women in the U.S. and Western 
Europe. Amplifi cation of the her-2/neu gene occurs in approximately 25% of 
invasive ductal carcinomas of the breast. Th e fi rst HER-2/neu-targeted approach 
to reach the clinic was trastuzumab, a humanized monoclonal antibody directed 
against the extracellular domain of the HER-2/neu protein. Trastuzumab therapy 
prolongs the survival of patients with metastático HER-2/neu-overexpressing breast 
cancer when combined with chemotherapy and has recently been demonstrated 
to lead to dramatic improvements in disease-free survival when used in the 
adjuvant therapy setting in combination with or following chemotherapy. Here, 
we performed a meta-analysis of completed clinical trials of adjuvant trastuzumab 
in the adjuvant setting. Survival, recurrence, brain metastases, cardiotoxicity and 
directions for future research are discussed.
A meta-analysis of randomized controlled trials (RCT) was performed 
comparing adjuvant trastuzumab treatment for HER2-positive early breast 
cancer (EBC) to observation. Th e MEDLINE, EMBASE, CANCERLIT and 
Cochrane Library databases, and abstracts published in the annual proceedings 
were systematically searched for evidence. Relevant reports were reviewed by two 
reviewers independently and the references from these reports were searched for 
additional trials, using guidelines set by QUOROM statement criteria.
Pooled results from that fi ve randomized trials of adjuvant Trastuzumab showed 
a signifi cant reduction of mortality (p < 0.00001), recurrence (p < 0.00001), 
metastases rates (p < 0.00001) and second tumors other than breast cancer 
(p = 0.007) as compared to no adjuvant Trastuzumab patients. Th ere were more 
grade III or IV cardiac toxicity after trastuzumab (203/4555 = 4.5%) versus no 
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trastuzumab (86/4562 = 1.8%). Th e likelihood of cardiac toxicity was 2.45-fold 
higher (95% CI 1.89 – 3.16) in trastuzumab arms, however that result was 
associated with heterogeneity. Th e likelihood of brain metastases was 1.82-fold 
higher (95% CI 1.16 – 2.85) in patients who received trastuzumab.
Th e results from this meta-analysis are suffi  ciently compelling to consider 
1 year of adjuvant trastuzumab treatment for women with HER-2-positive EBC 
based on the risk: benefi t ratio demonstrated in these studies. Adequate assessment 
of HER-2/neu status is critical, and careful cardiac monitoring is warranted 
because of cardiac toxicity. Clinical trials should be designed to answer unsolved 
questions.
Slamon D, Eiermann W, Robert N, Pienkowski T (2011) Adjuvant trastuzumab 
in HER2-positive breast cancer. N Engl J Med 365: 1273-83
Trastuzumab improves survival in the adjuvant treatment of HER-positive breast 
cancer, although combined therapy with anthracycline-based regimens has been 
associated with cardiac toxicity. We wanted to evaluate the effi  cacy and safety of 
a new nonanthracycline regimen with trastuzumab.
We randomly assigned 3222 women with HER2-positive early-stage breast 
cancer to receive doxorubicin and cyclophosphamide followed by docetaxel every 
3 weeks (AC-T), the same regimen plus 52 weeks of trastuzumab (AC-T plus 
trastuzumab), or docetaxel and carboplatin plus 52 weeks of trastuzumab (TCH). 
Th e primary study end point was disease-free survival. Secondary end points were 
overall survival and safety.
At a median follow-up of 65 months, 656 events triggered this protocol-
specifi ed analysis. Th e estimated disease-free survival rates at 5 years were 
75% among patients receiving AC-T, 84% among those receiving AC-T plus 
trastuzumab, and 81% among those receiving TCH. Estimated rates of overall 
survival were 87%, 92%, and 91%, respectively. No signifi cant diff erences in 
effi  cacy (disease-free or overall survival) were found between the two trastuzumab 
regimens, whereas both were superior to AC-T. Th e rates of congestive heart 
failure and cardiac dysfunction were signifi cantly higher in the group receiving 
AC-T plus trastuzumab than in the TCH group (P<0.001). Eight cases of acute 
leukemia were reported: seven in the groups receiving the anthracycline-based 
regimens and one in the TCH group subsequent to receiving an anthracycline 
outside the study.
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Th e addition of 1 year of adjuvant trastuzumab signifi cantly improved disease-
free and overall survival among women with HER2-positive breast cancer. Th e 
risk-benefi t ratio favored the nonanthracycline TCH regimen over AC-T plus 
trastuzumab, given its similar effi  cacy, fewer acute toxic eff ects, and lower risks of 
cardiotoxicity and leukemia. (Funded by Sanofi -Aventis and Genentech; BCIRG-
006 ClinicalTrials.gov number, NCT00021255.).
Burstein HJ (2011) Patients with anti-HER2 responsive disease: defi nition 
and adjuvant therapies. Breast 20 (Suppl 3): S132-4
Treatment of HER2 positive breast cancer is one of the great successes in recent 
breast oncology. Th is article will review recent information on patient and tumor 
selection for anti-HER2 therapy, and new data on optimal use of trastuzumab-
based treatments in the adjuvant setting.
Constantinidou A, Smith I (2011) Is there a case for anti-HER2 therapy 
without chemotherapy in early breast cancer? Breast 20 (Suppl 3): S158-61
Trastuzumab in combination with chemotherapy is now standard of care for 
patients with early HER2-positive cancers larger than 1 cm. Some patients 
however may not need or simply may not want chemotherapy with its associated 
toxicities. For example patients with small (< 1 cm.Tla.b) node-negative (NO) 
HER2-positive cancers were largely excluded from all the large randomized 
adjuvant trastuzumab trials on the basis of perceived excellent prognosis, yet 
recently several retrospective studies have suggested that this is not always the 
case and more active adjuvant treatment including anti-HER2 therapy may 
be warranted. Subset analysis of one trastuzumab trial (HERA) demonstrated 
that patients with 1-2 cm cancers derived at least as much clinical benefi t from 
1-year of adjuvant trastuzumab with chemotherapy as the overall cohort and 
2  retrospective audits have confi rmed this. Anti-HER2 therapy including 
both trastuzumab and lapatinib alone has established clinical effi  cacy in 
metastatic disease, with response rates of up to 35% and with some long term 
remissions. Combination anti-HER2 therapy with trastuzumab/lapatinib and 
with trastuzumab/pertuzumab have also been shown to have effi  cacy as second 
line treatment inpatients after trastuzumab. Trastuzumab and Lapatinib have 
each been shown to improve time to progression and response rate when given 
with anastrazole and letrozole respectively as fi rst line treatment for metastatic 
ER-positive HER2-positive disease. In neoadjuvant trials the combination of 
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trastuzumab and pertuzumab without chemotherapy have achieved pathological 
complete remission rates in a signifi cant minority of patients, suggesting that a 
subgroup exists for whom anti-HER2 therapy alone may be as eff ective as with 
additional chemotherapy. Trials and prospective studies are now warranted to 
investigate this issue further in selected patients and these must be accompanied 
by tissue collection to try to identify predictive biomarkers. Meanwhile there is 
already enough circumstantial evidence to justify anti-HER2 therapy alone in 
selected patients for whom chemotherapy is contraindicated.
von Minckwitz G, Loibl S, Maisch A, Untch M (2011) Lessons from the 
neoadjuvant setting on how best to choose adjuvant therapies. Breast 20 
(Suppl 3): S142-5
To review the recent literature on neoadjuvant treatment of breast cancer with 
respect to insights that might be used for better using systemic treatment in early 
breast cancer.
Much more insight was gained during recent years on how to use information 
on pathologic complete response (pCR). pCR appears to be a valid surrogate for 
long-term survival mainly in triple-negative and HER2-positive disease. Patient 
with breast cancer of these subtypes can be relieved from poor prognosis if they 
achieve a pCR after neoadjuvant treatment. It can even be speculated that the 
extent of local and post-surgical systemic treatment can be further reduced. 
Patients without pCR show a high risk of early recurrence and are at high need 
for new treatment options. Th ese advantages lead to the recommendation that use 
of neoadjuvant treatment should not be indicated by tumor size but far more by 
tumor subtype. As pCR appears to be more sensitive to detect treatment eff ects 
than disease-free survival, the neoadjuvant approach identifi es easier promising 
treatments and can even discriminate optimal approaches for biologically defi ned 
subgroups. A recent meta-analysis examining pattern of neoadjuvant chemotherapy 
suggests that luminal-B type tumors require longer duration of treatment, triple-
negative tumors require dose-intensifi ed anthracycline-taxane-based treatment 
of only short duration, and HER2-positive tumors require longer duration (if 
hormone-receptor positive) and an optimal dose of taxanes. As biomarkers can 
be easily assessed on tumor tissue before, during, and after treatment, there is 
increasing data available on markers that e.g. potentially predict resistance to 
anti-HER2 treatment, predict response to anti-angiogenic drugs as well as effi  cacy 
of PARP inhibitors. Validation of these candidate markers remains a challenging 
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task, as patients cohort are usually small and fi nding studies are compromised 
by multiple testing.
With the acquired new knowledge from neoadjuvant studies will help to 
individualize treatment based on biological behavior of breast cancer subtypes.
Jelovac D, Wolff  AC (2012) Th e adjuvant treatment of HER2-positive breast 
cancer. Curr Treat Options Oncol 13: 230-9
About 15-20% of patients with early stage breast cancer present with tumors 
that have overexpression or amplifi cation of the human epidermal growth factor 
receptor 2 (HER2) gene. Before 2005, these individuals had an increased risk of 
recurrence and death, but since then their outcomes have substantially improved 
with the adoption in most countries of adjuvant trastuzumab as a standard 
component of therapy for HER2-positive early-stage breast cancer. Consequently, 
access to high-quality and accurate HER2 testing methods is critical to accurately 
determine HER2 status, guide treatment decisions, and ultimately improve clinical 
outcomes. In 2012, the humanized monoclonal anti-HER antibody trastuzumab 
was the only approved HER2-targeted therapy in the adjuvant setting. Data from 
the fi rst generation of trials combining it with various chemotherapy regimens 
showed signifi cant improvements in disease-free and overall survival (DFS/OS). 
Based on results from fi ve randomized clinical trials, a trastuzumab-containing 
regimen for up to 1 year is now considered standard for all patients with HER2-
positive tumors larger than 1 cm in size who would have fulfi lled eligibility to 
those studies, and this recommendation is sometimes extended to patients with 
stage I tumors greater than 0.5 cm (T1b). Second generation adjuvant studies 
with other HER2-targeted agents like lapatinib and pertuzumab are ongoing, and 
newer drugs like T-DM1 and neratinib are being actively tested in the metastatic 
setting.
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